Literature DB >> 378369

Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations.

H L Davis, T E Davis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 378369

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  20 in total

1.  Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin.

Authors:  R Supino; M Mariani; E Prosperi; G Parmiani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Aspects of the chemical stability of doxorubicin and seven other anthracyclines in acidic solution.

Authors:  J H Beijnen; G Wiese; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1985-06-21

3.  Genetic variants contributing to daunorubicin-induced cytotoxicity.

Authors:  R Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

4.  A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.

Authors:  W Bolanowska; T Gessner; H Preisler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 5.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Anthracycline cardiomyopathy.

Authors:  N L Kobrinsky; N K Ramsay; W Krivit
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

8.  Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.

Authors:  N Hartman; P J Basseches; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

9.  Comparison of the intracellular pharmacokinetics of doxorubicin and 4'-epi-doxorubicin in patients with acute leukemia.

Authors:  U Tidefelt; B Sundman-Engberg; C Paul
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 10.  N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence.

Authors:  Hesamoddin Hosseinjani; Azadeh Moghaddas; Hossein Khalili
Journal:  Eur J Clin Pharmacol       Date:  2013-03-19       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.